Lack of hippocampal CB1 receptor desensitization by Δ9-tetrahydrocannabinol in aged mice and by low doses of JZL 184

[1]  T. Vasiljevik,et al.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. , 2015, Pharmacological research.

[2]  B. Lutz,et al.  Age-related changes in the endocannabinoid system in the mouse hippocampus , 2015, Mechanisms of Ageing and Development.

[3]  M. Usami,et al.  MAM-2201, a synthetic cannabinoid drug of abuse, suppresses the synaptic input to cerebellar Purkinje cells via activation of presynaptic CB1 receptors , 2015, Neuropharmacology.

[4]  V. Marzo,et al.  Endocannabinoid signalling and the deteriorating brain , 2014, Nature Reviews Neuroscience.

[5]  W. Fratta,et al.  The role of the endocannabinoid system in eating disorders: neurochemical and behavioural preclinical evidence. , 2014, Current pharmaceutical design.

[6]  G. Panagis,et al.  Regulation of brain reward by the endocannabinoid system: a critical review of behavioral studies in animals. , 2014, Current pharmaceutical design.

[7]  D. Piomelli.  More surprises lying ahead. The endocannabinoids keep us guessing , 2014, Neuropharmacology.

[8]  K. Dou,et al.  Decreased pain threshold and enhanced synaptic transmission in the anterior cingulate cortex of experimental hypothyroidism mice , 2014, Molecular pain.

[9]  Stephen PH Alexander,et al.  The Concise Guide to Pharmacology 2013/14: G Protein-Coupled Receptors , 2013, British journal of pharmacology.

[10]  B. Fleischmann,et al.  Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction , 2013, Proceedings of the National Academy of Sciences.

[11]  P. Nicotera,et al.  Loss of CB1 receptors leads to decreased cathepsin D levels and accelerated lipofuscin accumulation in the hippocampus , 2013, Mechanisms of Ageing and Development.

[12]  D. Selley,et al.  Repeated Low-Dose Administration of the Monoacylglycerol Lipase Inhibitor JZL184 Retains Cannabinoid Receptor Type 1–Mediated Antinociceptive and Gastroprotective Effects , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[13]  B. Cravatt,et al.  Chemical Probes of Endocannabinoid Metabolism , 2013, Pharmacological Reviews.

[14]  D. Selley,et al.  Brain regional differences in CB1 receptor adaptation and regulation of transcription. , 2013, Life sciences.

[15]  B. Cravatt,et al.  The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. , 2013, Life sciences.

[16]  E. Patsouris,et al.  The role of endocannabinoids in pain modulation , 2013, Fundamental & clinical pharmacology.

[17]  R. Maldonado,et al.  Dissociation of the Pharmacological Effects of THC by mTOR Blockade , 2013, Neuropsychopharmacology.

[18]  R. Mechoulam,et al.  The endocannabinoid system and the brain. , 2013, Annual review of psychology.

[19]  B. Gorzalka,et al.  Temporal changes in N‐acylethanolamine content and metabolism throughout the peri‐adolescent period , 2013, Synapse.

[20]  R. Maldonado,et al.  Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[21]  A. Bilkei-Gorzo,et al.  The endocannabinoid system in normal and pathological brain ageing , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[22]  O. Albayram,et al.  Loss of CB1 receptors leads to differential age-related changes in reward-driven learning and memory , 2012, Front. Ag. Neurosci..

[23]  M. Webster,et al.  Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex , 2012, BMC Neuroscience.

[24]  Peter T. Nguyen,et al.  β-Arrestin2 Regulates Cannabinoid CB1 Receptor Signaling and Adaptation in a Central Nervous System Region–Dependent Manner , 2012, Biological Psychiatry.

[25]  M. Kano,et al.  Endocannabinoids and Retrograde Modulation of Synaptic Transmission , 2012, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[26]  W. Maier,et al.  Early onset of aging-like changes is restricted to cognitive abilities and skin structure in Cnr1−/− mice , 2012, Neurobiology of Aging.

[27]  B. Lutz,et al.  The endocannabinoid system in anxiety, fear memory and habituation , 2012, Journal of psychopharmacology.

[28]  Xin Xin,et al.  Molecular and cellular mechanisms of the age-dependency of opioid analgesia and tolerance , 2012, Molecular pain.

[29]  Beat Lutz,et al.  Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging , 2011, Proceedings of the National Academy of Sciences.

[30]  Stephen P. H. Alexander,et al.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.

[31]  W. A. Wilson,et al.  Role of Cannabinoid Receptor Type 1 Desensitization in Greater Tetrahydrocannabinol Impairment of Memory in Adolescent Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.

[32]  P. Strange.  Use of the GTPγS ([35S]GTPγS and Eu‐GTPγS) binding assay for analysis of ligand potency and efficacy at G protein‐coupled receptors , 2010, British journal of pharmacology.

[33]  Peter T. Nguyen,et al.  Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system , 2010, Nature Neuroscience.

[34]  L. Parsons,et al.  Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls , 2010, British journal of pharmacology.

[35]  Benjamin F. Cravatt,et al.  Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects , 2008, Nature chemical biology.

[36]  D. Selley,et al.  Dose-Related Differences in the Regional Pattern of Cannabinoid Receptor Adaptation and in Vivo Tolerance Development to Δ9-Tetrahydrocannabinol , 2008, Journal of Pharmacology and Experimental Therapeutics.

[37]  L. Brandenburg,et al.  Role of receptor internalization in the agonist‐induced desensitization of cannabinoid type 1 receptors , 2008, Journal of neurochemistry.

[38]  S. Werner,et al.  Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System , 2007, Science.

[39]  D. Selley,et al.  Prolonged Recovery Rate of CB1 Receptor Adaptation after Cessation of Long-Term Cannabinoid Administration , 2006, Molecular Pharmacology.

[40]  O. Valverde,et al.  Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Moriyama,et al.  Age-Dependent Opioid Escalation in Chronic Pain Patients , 2005, Anesthesia and analgesia.

[42]  M. Cebeira,et al.  Cannabinoid tolerance and dependence: A review of studies in laboratory animals , 2005, Pharmacology Biochemistry and Behavior.

[43]  Manohar Sharma,et al.  Age-Dependent Morphine Tolerance Development in the Rat , 2005, Anesthesia and analgesia.

[44]  R. Pertwee,et al.  Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. , 2005, Life sciences.

[45]  D. Selley,et al.  Signaling pathways involved in the development of cannabinoid tolerance. , 2004, Trends in pharmacological sciences.

[46]  Á. Pazos,et al.  Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain , 2004, Neuropharmacology.

[47]  A. Thompson,et al.  The therapeutic potential of cannabis , 2003, The Lancet Neurology.

[48]  Lei Wang,et al.  Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[50]  J. Guimón,et al.  Effects of Age, Postmortem Delay and Storage Time on Receptor-mediated Activation of G-proteins in Human Brain , 2002, Neuropsychopharmacology.

[51]  C. Breivogel,et al.  Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. , 2001, Molecular pharmacology.

[52]  C. Bass,et al.  Time course for the induction and maintenance of tolerance to Δ9-tetrahydrocannabinol in mice , 2000 .

[53]  Rodney J. Moore,et al.  Agonist-stimulated [35S]GTPγS binding in brain Modulation by endogenous adenosine , 2000, Neuropharmacology.

[54]  M. Herkenham,et al.  Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[55]  R. Hampson,et al.  Effects of Chronic Treatment with Δ9-Tetrahydrocannabinol on Cannabinoid-Stimulated [35S]GTPγS Autoradiography in Rat Brain , 1996, The Journal of Neuroscience.

[56]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[57]  J. Bains,et al.  Neurobiological Interactions Between Stress and the Endocannabinoid System , 2016, Neuropsychopharmacology.

[58]  P. Skudlarski,et al.  Early age-related cognitive impairment in mice lacking cannabinoid CB 1 receptors , 2005 .

[59]  B. Szabo,et al.  Effects of cannabinoids on neurotransmission. , 2005, Handbook of experimental pharmacology.

[60]  Franjo Grotenhermen,et al.  Pharmacokinetics and Pharmacodynamics of Cannabinoids , 2003, Clinical pharmacokinetics.

[61]  L. Sim-Selley,et al.  Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. , 2003, Critical reviews in neurobiology.